Recent

% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

  • mwindsweptfarm@comcast.net mwindsweptfarm Oct 14, 2013 7:10 AM Flag

    Some insight....

    Oncologists know that approval is right around the corner. They are actually prescribing a "temporary" med and telling patients that they will put them on Ibrutinib very soon upon approval. That is how quick they will be able to get the product out and rolling. Sales will be amazing. I predict an initial pop up but steady growth starting immediately.

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • mwind--"telling patients they will put them on ibrutinib.... " how do you know this? guessing or fact? TIA

      • 2 Replies to centerdir
      • mwindsweptfarm@comcast.net mwindsweptfarm Oct 15, 2013 8:43 AM Flag

        I am dating an Oncologist. We have had this stock since it was 14.50 because of the game-changing promise it has shown. This is what he is hearing from his patients that are seeing other oncology specialists. This is how much they believe in this drug.

        Sentiment: Hold

      • Sound like doctors would.Medical experts say every year about 12,000 patients in the U.S. are diagnosed with chronic lymphocytic leukemia. But a new drug has shown promise for patients who've lost all hope of beating the disease.

        It's the simple things, like enjoying the outdoors and taking family vacations that 73-year-old Dennis Hickey can look forward to once again.

        "I can do my job, I sell houses,” says Dennis Hickey who has chronic lymphocytic leukemia. “I can enjoy the grandkids."

        Dennis has chronic lymphocytic leukemia, or CLL, a common and deadly form of leukemia affecting older adults.

        "The prognosis was not good," says Dennis.

        With six months to live, Dennis got to take an experimental drug called ibrutinib as part of a clinical trial for CLL patients.

        "We've seen a drug come into the clinic that has really helped patients with CLL and related diseases that have been at the end of their life," explains Dr. John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research at the Ohio State University Comprehensive Cancer Center.

        The drug works by targeting the protein in CLL cells. Without the protein, the cancer can't grow.

        Doctors say 90-percent of patients have had success with ibrutinib and side effects are minimal compared to chemotherapy.

        "Patients tolerate it very, very well,” says Dr. Byrd. “Many patients will say they feel like they did before they had CLL."

        Researchers say ibrutinib's a game changer. Dennis Hickey says it's a life saver.

        "I'm still here,” explains Dennis. “I look, I look back to it and say boy, I've been blessed, and I'm so thankful."

        Researchers say ibrutinib is not a cure, but if patients follow treatment, they can manage CLL the same way they would manage diabetes or high blood pressure. The drug is expected to be approved by the FDA

        Sentiment: Strong Buy

 
PCYC
257.100.00(0.00%)Apr 23 3:59 PMEDT